



**ELECTRONIC SUBMISSION FORM – DO NOT MODIFY**

Please ensure that you have turned **insert off (overtyping on)**.

The presenting author:

Surname: TOUMA Forename(s): ELIAS Title: DR

Address: Neonatal Screening Unit, Faculty of Medicine, University St. Joseph  
Damascus Street, National Museum District, Riad ElSolh 1107 2180

PO Box: 11-5076,

City and code: BEIRUT Country: LEBANON

Ph: +9611872158 Fax: +9611614054 Email: ehtouma@inco.com.lb

**X Poster presentation**

Oral Presentation at workshops (overtyping with a **X** one of the following boxes)

- |                                                          |                                                            |                                                          |
|----------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------|
| <input type="checkbox"/> Hypothyroidism and CAH          | <input checked="" type="checkbox"/> Hyperphenylalaninemias | <input type="checkbox"/> Cystic Fibrosis                 |
| <input type="checkbox"/> Quality control programs        | <input type="checkbox"/> New technologies                  | <input type="checkbox"/> Databases and newborn screening |
| <input type="checkbox"/> New paths in neonatal screening | <input type="checkbox"/> Tandem MS                         | <input type="checkbox"/> Screening for Type I Diabetes   |

The number of oral presentations is limited. Abstracts not accepted for oral presentation will be considered for poster presentation.

**Abstracts submission deadline: 15<sup>th</sup> January 2002**

Type your abstract inside the box according to the instructions

**EPIDEMIOLOGY OF HYPERPHENYLALANINEMIA (HPA) IN LEBANON.**

Touma E H<sup>1</sup>, Romstad A<sup>2</sup>, Khneisser I<sup>1</sup>, Hsiao K-J<sup>3</sup>, Loiselet J<sup>1</sup>, Dhondt J-L<sup>4</sup>

<sup>1</sup>Unité de Dépistage Néonatal, Faculté de Médecine, Université St. Joseph, Beirut, Lebanon. <sup>2</sup> John F Kennedy Institute, Glostrup, Denmark. <sup>3</sup> Clinical Biochemistry Research Laboratory, Veterans General Hospital, Taipei, Taiwan. <sup>4</sup> Laboratoire de Biochimie, Faculté Libre de Médecine, Lille, France.

During a 6-year period (1996-2001) about 60,000 newborns were screened using the enzymatic assay Quantase®. The cumulative incidence of HPA-PKU was 1/7500 (7 cases). Three cases were considered as mild benign HPA. In particular, the cumulative incidence of BH4-deficiency (1 case) and of classical PKU (3 cases) was 1/15000. The relative incidence of atypical PKU due to BH4 deficiencies was 25% while globally it is only 1-2%. This may be attributed to higher levels of consanguineous marriages in Lebanon.

Including the 7 cases diagnosed by neonatal screening, a total of 22 children in 19 families were followed for HPA under metabolic investigation or dietary monitoring. Of those, two infants had PKU with associated disorders: fatal intestinal dysplasia in one and cardiomyopathy in another. Only one of five infants who had mild benign persistent HPA needed special low PA diet because of blood PA levels above 360 µmol/L.

Tetrahydrobiopterin (BH4) deficiencies were determined in three infants who were investigated for HPA. The first case had GTP cyclohydrolase deficiency for which she received adequate treatment starting 5 months of age with normal growth and development at 5 years of age. DNA analysis revealed a homozygous mutation in exon 6, M213T (ATG → ACG) not described previously. The second case, with 6-pyruvoyl-tetrahydropterin synthase (6PTPS) deficiency, was diagnosed at 8 months of age but she was not adequately treated and died at age 1.5 years. DNA analysis demonstrated a homozygous mutation C to T at cDNA position 200 within the exon 4 of the PTPS gene. The third case was detected by neonatal screening and confirmed as Dihydropteridine reductase deficiency at 1 month of age. DNA analysis revealed two distinct mutations R221X and Y150C, the first being a severe mutation inherited from the mother while the second a milder one. The patient responded well to low-PA diet and special treatment by BH4, L-Dopa+carbidopa, 5-OH Tryptophane, Selegeline and folic acid with normal development at 2 years of age.

Save this file as your\_name.rtf and send it as attachment by e-mail to [isns2002@ospedale-gaslini.ge.it](mailto:isns2002@ospedale-gaslini.ge.it)

No. 217